23
23
26
26
22
22
23
23
25
25
23
23
31
31
33
33
28
28
6
6
2020
2011
Company (326)University (9)Research Institution (3)
1 - 10 of 326
Sort by
SEC Filing
Accession Number0001140361-20-010906Form Type10-QAcceptance Date2020-05-07
--- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.:001-34079 Rexahn Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware …
SEC Filing
Accession Number0001140361-20-010048Form Type10-KAcceptance Date2020-04-29
--- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34079 Rexahn Pharmaceuticals, Inc. (Exact name of registrant as specified in its c…
SEC Filing
Accession Number0001140361-20-008410Form Type8-KAcceptance Date2020-04-09
--- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2020 Rexahn Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 15245 Shady Grove Road, Suite 4…
SEC Filing
Accession Number0001140361-20-005875Form Type8-KAcceptance Date2020-03-16
--- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2020 Rexahn Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 15245 Shady Grove Road, Suite…
Patent
Publication NumberUS 10570101Filing StatusIssued PatentAvailabilityUnknownFiling Date2018-04-06Publication Date2020-02-25
The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
SEC Filing
Accession Number0001140361-20-002721Form Type8-KAcceptance Date2020-02-10
--- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2020 Rexahn Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34079 11-3516358 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 15245 Shady Grove Road, Suite …
Patent
Publication NumberCA 2913611 CFiling StatusIssued PatentAvailabilityUnknownFiling Date2014-06-27Publication Date2019-12-24
The present invention relates to storage stable nanoparticulate compositions of piperazine compounds. The pharmaceutical compositions comprising the nanoparticulate compositions that are useful for the treatment and prevention of proliferative diseases including cancer are also described.
SEC Filing
Accession Number0001140361-19-019932Form Type10-QAcceptance Date2019-11-06
--- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.:001-34079 Rexahn Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delawar…
Patent
Publication NumberBR PI1013901 A2Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2010-04-29Publication Date2019-09-24
The present invention generally relates to use of a stable solid pharmaceutical compositions that includes a clavulanate as the pharmaceutically active ingredients in an immediate-release or an extended-release solid dosage form. The composition can be used in a method of treating a neurodegenerative disease, providing neuroprotection, or preventing neuronal cell loss or death. Exemplary neurodegenerative diseases include Parkinson's disease, Alzheimer's disease and multiple sclerosis.
Patent
Publication NumberUS 20190275042Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2019-03-18Publication Date2019-09-12
The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.
We found 326 documents that match your Search
Patents: 152
Clinical Trials: 9
SEC Filings: 165

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in